108
Participants
Start Date
January 31, 2006
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2008
E7389
Intravenous 1.4 mg/m2 on a 3-week course.
St. Luke's Roosevelt Hospital Center, New York
Columbia University Medical Center, New York
New York Oncology Hematology, P.C., Albany
Virginia Oncology Associates, Norfolk
Raleigh Hematology Oncology Associates PL, Raleigh
Melbourne Internal Medicine Associates, Melbourne
Minnesota Hematology Oncology, Burnsville
Ocala Oncology Center PL, Ocala
Central Indiana Cancer Centers, Indianapolis
Missouri Cancer Associates, Columbia
US Oncology, Dallas
Mary Crowley Medical Research Center, Dallas
Texas Oncology PA, Tyler
Tyler Cancer Center, Tyler
Texas Oncology PA, Fort Worth
Deke Slayton Cancer Center, Webster
El Paso Cancer Treatment Center, El Paso
Dr. Robert Jotte, Denver
Eisai Inc.
INDUSTRY